News
CAR T-cell therapy eyed for CLL patients with residual disease
Key clinical point: CAR T-cell therapy may be an option for chronic lymphocytic leukemia patients with residual disease after upfront therapy....
News
Three-drug regimen boosts progression-free survival in patients with relapsed CLL and adverse prognostic features
Key clinical point: Progression-free survival was improved for poor prognosis patients with relapsed chronic lymphocytic leukemia when idelalisib...
News
Treatment-free remissions achieved in patients with chronic myeloid leukemia
Key clinical point: Treatment-free remission attempts are safe and are achievable in most patients with chronic myeloid leukemia in chronic phase...
News
Smoldering multiple myeloma affects 1 in 7 patients
Key clinical point: The prevalence of smoldering multiple myeloma varied among various socio- and geodemographic subgroups, but overall survival...
News
Mechanism proposed for microvascular thrombosis in thrombotic thrombocytopenic purpura
Key clinical point: In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins...
News
Dematin key to erythrocyte membrane stability in mice
Key clinical point: Dematin is newly recognized as a protein crucial to the integrity of red blood cell membranes. Major finding: Dematin’s...
News
Adding obinutuzumab to bendamustine boosts progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma
Key clinical point: Obinutuzumab is an option when patients with indolent non-Hodgkin lymphoma relapse or don’t achieve adequate disease control...
News
Acalabrutinib shows efficacy as monotherapy in untreated CLL
Key clinical point: Acalabrutinib, which has shown efficacy in relapsed CLL, has now shown efficacy as a monotherapy for patients with previously...
News
Ibrutinib at below standard dose may achieve good survival in CLL
Key clinical point: Ibrutinib given at doses lower than the standard dose of 420 mg/day may achieve comparable overall survival and progression-...
News
Mogamulizumab achieves objective responses in relapsed/refractory adult T-cell leukemia-lymphoma
Key clinical point: The anti-CCR4 monoclonal antibody mogamulizumab was superior to other investigator-selected therapies for the treatment of...
News
Alemtuzumab plus CHOP didn’t boost survival in elderly patients with peripheral T-cell lymphomas
Key clinical point: Adding the monoclonal anti-CD52 antibody alemtuzumab to CHOP (A-CHOP) increased response rates in elderly patients with...
News
Antibodies cut factor VIII half-life in patients with hemophilia A
Key clinical point: Non-neutralizing, factor VIII–specific IgG antibodies can contribute significantly to reductions in factor VIII half-life in...
News
Maintenance rituximab extends progression-free but not overall survival in CLL
Key clinical point: Progression-free survival, but not overall survival, was improved after 2 years of maintenance immunotherapy with rituximab....
News
Brentuximab vedotin boosted PET-negative rate in Hodgkin
Key clinical point: Brentuximab vedotin appears to eradicate residual disease after induction chemotherapy in a small study of patients with...